OBJECTIVES: Monocytes and macrophages produce interleukin-1β by inflammasome activation which involves adenosine triphosphate release, pannexin-1 channels, and P2X7 receptors. However, interleukin-1β can also be produced in an inflammasome-independent fashion. Here we studied if this mechanism also involves adenosine triphosphate signaling and how it contributes to inflammasome activation. DESIGN: In vitro studies with human cells and randomized animal experiments. SETTING: Preclinical academic research laboratory. SUBJECTS: Wild-type C57BL/6 and pannexin-1 knockout mice, healthy human subjects for cell isolation. INTERVENTIONS: Human monocytes and U937 macrophages were treated with different inhibitors to study how purinergic signaling contributes to toll-like receptor-induced cell activation and interleukin-1β production. Wild-type and pannexin-1 knockout mice were subjected to cecal ligation and puncture to study the role of purinergic signaling in interleukin-1β production and host immune defense. MEASUREMENTS AND MAIN RESULTS: Toll-like receptor agonists triggered mitochondrial adenosine triphosphate production and adenosine triphosphate release within seconds. Inhibition of mitochondria, adenosine triphosphate release, or P2 receptors blocked p38 mitogen-activated protein kinase and caspase-1 activation and interleukin-1β secretion. Mice lacking pannexin-1 failed to activate monocytes, to produce interleukin-1β, and to effectively clear bacteria following cecal ligation and puncture. CONCLUSIONS: Purinergic signaling has two separate roles in monocyte/macrophage activation, namely to facilitate the initial detection of danger signals via toll-like receptors and subsequently to regulate nucleotide-binding oligomerization domain, leucine rich repeat and pyrin domain containing 3 inflammasome activation. Further dissection of these mechanisms may reveal novel therapeutic targets for immunomodulation in critical care patients.
OBJECTIVES: Monocytes and macrophages produce interleukin-1β by inflammasome activation which involves adenosine triphosphate release, pannexin-1 channels, and P2X7 receptors. However, interleukin-1β can also be produced in an inflammasome-independent fashion. Here we studied if this mechanism also involves adenosine triphosphate signaling and how it contributes to inflammasome activation. DESIGN: In vitro studies with human cells and randomized animal experiments. SETTING: Preclinical academic research laboratory. SUBJECTS: Wild-type C57BL/6 and pannexin-1 knockout mice, healthy human subjects for cell isolation. INTERVENTIONS:Human monocytes and U937 macrophages were treated with different inhibitors to study how purinergic signaling contributes to toll-like receptor-induced cell activation and interleukin-1β production. Wild-type and pannexin-1 knockout mice were subjected to cecal ligation and puncture to study the role of purinergic signaling in interleukin-1β production and host immune defense. MEASUREMENTS AND MAIN RESULTS: Toll-like receptor agonists triggered mitochondrial adenosine triphosphate production and adenosine triphosphate release within seconds. Inhibition of mitochondria, adenosine triphosphate release, or P2 receptors blocked p38 mitogen-activated protein kinase and caspase-1 activation and interleukin-1β secretion. Mice lacking pannexin-1 failed to activate monocytes, to produce interleukin-1β, and to effectively clear bacteria following cecal ligation and puncture. CONCLUSIONS: Purinergic signaling has two separate roles in monocyte/macrophage activation, namely to facilitate the initial detection of danger signals via toll-like receptors and subsequently to regulate nucleotide-binding oligomerization domain, leucine rich repeat and pyrin domain containing 3 inflammasome activation. Further dissection of these mechanisms may reveal novel therapeutic targets for immunomodulation in critical care patients.
Authors: Yu Chen; Ross Corriden; Yoshiaki Inoue; Linda Yip; Naoyuki Hashiguchi; Annelies Zinkernagel; Victor Nizet; Paul A Insel; Wolfgang G Junger Journal: Science Date: 2006-12-15 Impact factor: 47.728
Authors: Linda Yip; Tobias Woehrle; Ross Corriden; Mark Hirsh; Yu Chen; Yoshiaki Inoue; Vhe Ferrari; Paul A Insel; Wolfgang G Junger Journal: FASEB J Date: 2009-02-11 Impact factor: 5.191
Authors: Mihai G Netea; Claudia A Nold-Petry; Marcel F Nold; Leo A B Joosten; Bastian Opitz; Jonathan H M van der Meer; Frank L van de Veerdonk; Gerben Ferwerda; Bas Heinhuis; Isabel Devesa; C Joel Funk; Robert J Mason; Bart Jan Kullberg; Anna Rubartelli; Jos W M van der Meer; Charles A Dinarello Journal: Blood Date: 2008-12-22 Impact factor: 22.113
Authors: Xiaoou Li; Yutaka Kondo; Yi Bao; Laura Staudenmaier; Albert Lee; Jingping Zhang; Carola Ledderose; Wolfgang G Junger Journal: Crit Care Med Date: 2017-01 Impact factor: 7.598
Authors: Moritz M Gaidt; Thomas S Ebert; Dhruv Chauhan; Tobias Schmidt; Jonathan L Schmid-Burgk; Francesca Rapino; Avril A B Robertson; Matthew A Cooper; Thomas Graf; Veit Hornung Journal: Immunity Date: 2016-03-29 Impact factor: 31.745
Authors: Katarzyna Parzych; Anna V Zetterqvist; William R Wright; Nicholas S Kirkby; Jane A Mitchell; Mark J Paul-Clark Journal: FASEB J Date: 2017-02-28 Impact factor: 5.191
Authors: Koichiro Sueyoshi; Carola Ledderose; Yong Shen; Albert H Lee; Nathan I Shapiro; Wolfgang G Junger Journal: J Biol Chem Date: 2019-02-20 Impact factor: 5.157
Authors: Ross Luu; Silvana Valdebenito; Eliana Scemes; Antonio Cibelli; David C Spray; Maximiliano Rovegno; Juan Tichauer; Andrea Cottignies-Calamarte; Arielle Rosenberg; Calude Capron; Sandrine Belouzard; Jean Dubuisson; Djillali Annane; Geoffroy Lorin de la Grandmaison; Elisabeth Cramer-Bordé; Morgane Bomsel; Eliseo Eugenin Journal: iScience Date: 2021-11-19